Human cathelicidin antimicrobial peptide is up-regulated in the eosinophilic mucus subgroup of chronic rhinosinusitis patients

American Journal of Rhinology

Volumn 21, Issue 4, 2007, Pages 395-401

  Eng, Hooi Ooi ^a   Wormald, Peter John ^a,c   Carney, A Simon ^a   James, Craig Lloyd ^b   Lor, Wai Tan ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Adelaide Pathology Partners   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Allergic fungal sinusitis; Antimicrobial peptides; Cathelicidins; Chronic rhinosinusitis; hCAP18; LL 37; PCR

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; HOST RESISTANCE; HUMAN; HUMAN TISSUE; IMMUNITY; IMMUNOASSAY; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; NASAL BIOPSY; NOSE MUCOSA; NOSE POLYP; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHINOSINUSITIS; UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIMICROBIAL CATIONIC PEPTIDES; BLOTTING, WESTERN; CHRONIC DISEASE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NASAL MUCOSA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHINITIS; RNA, MESSENGER; SINUSITIS; UP-REGULATION;

EID: 34548445081     PISSN: 10506586     EISSN: None     Source Type: Journal    
DOI: 10.2500/ajr.2007.21.3048     Document Type: Article

References (24)

1. Anand VK. Epidemiology and economic impact of rhinosinusitis. Ann Otol Rhinol Laryngol Suppl 193:3-5, 2004.
2. Medzhitov R, and Janeway C Jr. Innate immune recognition: Mechanisms and pathways. Immunol Rev 173:89-97, 2000.
3. Kaliner MA. Human nasal host defense and sinusitis. J Allergy Clin Immunol 90:424-430, 1992.
4. Cole AM, Liao HI, Stuchlik O, et al. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol 169:6985-6991, 2002.
5. Bals R, Wang X, Zasloff M, et al. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci U S A 95:9541-9546, 1998.
6. Marchini G, Lindow S, Brismar H, et al. The newborn infant is protected by an innate antimicrobial barrier: Peptide antibiotics are present in the skin and vernix caseosa. Br J Dermatol 147:1127-1134, 2002.
7. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 111:1665-1672, 2003.
8. Davidson DJ, Currie AJ, Reid GS, et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol 172:1146-1156, 2004.
9. Sorensen O, Arnljots K, Cowland JB, et al. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 90:2796-2803, 1997.
10. Agerberth B, Charo J, Werr J, et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte popula tions. Blood 96:3086-3093, 2000.
11. Frohm Nilsson M, Sandstedt B, Sorensen O, et al. The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect Immun 67:2561-2566, 1999.
12. Malm J, Sorensen O, Persson T, et al. The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. Infect Immun 68:4297-4302, 2000.
13. Chen PH, and Fang SY. The expression of human antimicrobial peptide LL-37 in the human nasal mucosa. Am J Rhinol 18:381-385, 2004.
14. Kim ST, Cha HE, Kim DY, et al. Antimicrobial peptide LL-37 is upregulated in chronic nasal inflammatory disease. Acta Otolaryngol 123:81-85, 2003.
15. Marple BF. Allergic fungal rhinosinusitis: Current theories and management strategies. Laryngoscope 111:1006-1019, 2001.
16. Ponikau JU, Sherris DA, Kern EB, et al. The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin Proc 74:877-884, 1999.
17. Collins M, Nair S, Smith W, et al. Role of local immunoglobulin E production in the pathophysiology of noninvasive fungal sinusitis. Laryngoscope 114:1242-1246, 2004.
18. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: Establishing definitions for clinical research and patient care. J Allergy Clin Immunol 114:155-212, 2004.
19. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347:1151-1160, 2002.
20. Livak KJ, and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408, 2001.
21. Sorensen O, Cowland JB, Askaa J, et al. An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. J Immunol Methods 206:53-59, 1997.
22. Dorschner RA, Pestonjamasp VK, Tamakuwala S, et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol 117:91-97, 2001.
23. Lysenko ES, Gould J, Bals R, et al. Bacterial phosphorylcholine decreases susceptibility to the antimicrobial peptide LL-37/hCAP18 expressed in the upper respiratory tract. Infect Immun 68:1664-1671, 2000.
24. Bals R, Weiner DJ, Meegalla RL, et al. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest 103:1113-1117, 1999.